Skip to main content

Advertisement

SpringerLink
Log in

Pelvic Exenteration for Anal and Urogenital Squamous Cell Carcinoma: Experience and Outcomes from an Exenteration Unit Over 12 Years

  • Urologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Pelvic exenteration has increasingly been shown to improve disease-free and overall survival for patients with locally advanced pelvic malignancies. Squamous cell carcinoma (SCC) is the second most common pelvic malignancy requiring exenteration.

Objective

The aim of this study was to report the clinical and oncological outcomes from patients treated with pelvic exenteration for anal and urogenital SCC from a single, high-volume unit.

Methods

A review of a prospectively maintained database from 1991 to 2018 at a high-volume specialised institution was performed. Primary endpoints included R0 resection rates, local recurrence and overall survival (OS) rates.

Results

From January 1999 to July 2018, 361 patients underwent pelvic exenteration of which 31 patients were identified with SCC (15 anal SCC, 16 urogenital SCC). The majority of patients were females (n = 24, 77.4%). Median age was 59 (range 35–81). Twenty-seven patients underwent resection with curative intent with an R0 resection rate of 81.5%. Four patients underwent a palliative procedure [R1 = 3 (8%), R2 = 1 (3.3%)]. Mean hospital length of stay was 32 days (range 8–122 days). Disease-free survival was significantly increased in anal SCC with no significant difference in OS compared to urogenital SCC (p = 0.03, p = 0.447 respectively). Advanced pathological T stage was associated with decreased OS (p = 0.023). In the curative intent group the disease-free survival and OS rate was 59.3% and 70% at 24 months, respectively.

Conclusion

Complete R0 resection is achievable in a high proportion of patients. Urogenital SCC is associated with significantly worse disease-free survival, and advanced T-stage was a significant prognostic factor for OS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brunschwig A. Complete excision of pelvic viscera in the male for advanced carcinoma of the sigmoid invading the urinary bladder. Ann Surg. 1949;129(4):499–504.

    Article  CAS  Google Scholar 

  2. Brown KGM, Solomon MJ, Koh CE. Pelvic exenteration surgery: the evolution of radical surgical techniques for advanced and recurrent pelvic malignancy. Dis Colon Rectum. 2017;60(7):745–54.

    Article  Google Scholar 

  3. Quyn AJ, Austin KK, Young JM, Badgery-Parker T, Masya LM, Roberts R, Solomon MJ. Outcomes of pelvic exenteration for locally advanced primary rectal cancer: overall survival and quality of life. Eur J Surg Oncol. 2016;42(6):823–8. https://doi.org/10.1016/j.ejso.2016.02.016.

    Article  CAS  PubMed  Google Scholar 

  4. PelvEx Collaborative. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration. Ann Surg. 2019;269(2):315–321.

    Article  Google Scholar 

  5. Ferenschild FTJ, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AMM, et al. Total pelvic exenteration for primary and recurrent malignancies. World J Surg. 2009;33(7):1502–8.

    Article  CAS  Google Scholar 

  6. Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ. The epidemiology of anal cancer. Sex Health. 2012;9(6):504–8.

    Article  Google Scholar 

  7. Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007. 25(5):361–7.

  8. Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51(10):1826–9.

    Article  CAS  Google Scholar 

  9. Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780–9.

  10. Eeson G, Foo M, Harrow S, McGregor G, Hay J. Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment. Am J Surg. 2011;201:628–33.

    Article  Google Scholar 

  11. van der Wal BCH, Cleffken BI, Gulec B, Kaufman HS, Choti MA. Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy. J Gastrointest Surg. 2001;5(4):383–7.

    Article  Google Scholar 

  12. Minhas, S., Kayes, O., Hegarty, P., Kumar, P., Freeman, A. and Ralph, D. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int. 2005;96:1040–3.

    Article  Google Scholar 

  13. Yang HY, Park SC, Hyun JH, Seo HK, Oh JH. Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer. Ann Surg Treat Res. 2015;89(3):131–7.

    Article  CAS  Google Scholar 

  14. Hall BL, Hamilton BH, Richards K, Bilimoria KY, Cohen ME, Ko CY. Does surgical quality improve in the American College of Surgeons National Surgical Quality Improvement Program: an evaluation of all participating hospitals. Ann Surg. 2009;250(3):363–76.

    PubMed  Google Scholar 

  15. Pawlik TM, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration for advanced pelvic malignancies. Ann Surg Oncol. 2006;13(5):612.

    Article  Google Scholar 

  16. Ogura A, Akiyoshi T, Konishi T, et al. Safety of laparoscopic pelvic exenteration with urinary diversion for colorectal malignancies. World J Surg. 2016;40(5):1236.

    Article  Google Scholar 

  17. Tan KK, Pal S, Lee PJ, Rodwell L, Solomon MJ. Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca—a single institution’s experience over 16 years. Colorectal Dis. 2013;15(10):1227–31.

    Article  CAS  Google Scholar 

  18. Aleksic I, Rais-Bahrami S, Daugherty M, Agarwal PK, Vourganti S, Bratslavsky G. Primary urethral carcinoma: a surveillance, epidemiology, and end results data analysis identifying predictors of cancer-specific survival. Urol Ann. 2018;10(2):170–74. https://doi.org/10.4103/ua.ua_136_17.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14(9):2527–39.

    Article  CAS  Google Scholar 

  20. Ajani JA, Winter KA, Gunderson LL, et al. Inter-group RTOG 98-11: a phase III randomized study of 5-fluoruracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol. 2006;24:180s.

    Google Scholar 

  21. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007; 68(3):794–800.

    Article  Google Scholar 

  22. Glynne-Jones R, James R, Meadows H, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. 2012 ASCO annual meeting. J Clin Oncol. 2012;30:abstr 4004.

  23. UKCCCR. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348:1049–54.

  24. SEER Stat Fact Sheets: Anal Cancer. NIH Surveillance, Epidemiology and End Results Program. http://seer.cancer.gov/statfacts/html/anus.html. Accessed 5 Sept 2018.

  25. Nelson AM, Albizu-Jacob A, Fenech AL, Chon HS, Wenham RM, Donovan KA. Quality of life after pelvic exenteration for gynecologic cancer: findings from a qualitative study. Psychooncology. 2018;27(10):2357–62. https://doi.org/10.1002/pon.4832.

    Article  PubMed  Google Scholar 

  26. Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, et al. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018;149(3):484–490. https://doi.org/10.1016/j.ygyno.2018.03.054.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lau YC, Brown KG, Lee P. Pelvic exenteration for locally advanced and recurrent rectal cancer—How much more? J Gastrointest Oncol. 2019. https://doi.org/10.21037/jgo.2019.01.21.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Lago V, Poveda I, Padilla-Iserte P, et al. Pelvic exenteration in gynecologic cancer: complications and oncological outcome. Gynecol Surg. 2019;16:1. https://doi.org/10.1186/s10397-019-1055-y.

    Article  Google Scholar 

  29. Diver EJ, Rauh-Hain JA, Del Carmen MG. Total pelvic exenteration for gynecologic malignancies. Int J Surg Oncol. 2012;2012:693535.

    PubMed  PubMed Central  Google Scholar 

  30. Ahmadi N, Tan K-K, Solomon MJ, Al-Mozany N, Carter J. Pelvic exenteration for primary and recurrent gynecologic malignancies is safe and achieves acceptable long-term outcomes. J Gynecol Surg. 2014;30(5):255–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Oncology Unit, Peter MacCallum Cancer Centre, Melbourne, Australia

    Nicholas Smith MBBS, FRACS, Peadar S. Waters MB, BCh, BAO, MD, MCH, MedED, FRCS, Oliver Peacock BMBS, PhD, FRCS, Joseph C. Kong MBBS, FRACS, Jacob McCormick MBBS, FRACS, Satish K. Warrier MBBS, MS, FRACS, Orla McNally MBBAO, BCh, FRCSI, MRCOG, FRANZCOG, CGO, Andrew C. Lynch MBChB, MMedSc, FRACS & Alexander G. Heriot MA, MB, BChir, MD, MBA, FRCS (Gen.), FRCSEd, FRACS, FACS

  2. Department of Obstetrics and Gynaecology, Royal Women’s Hospital, Parkville, Victoria, Australia

    Orla McNally MBBAO, BCh, FRCSI, MRCOG, FRANZCOG, CGO

  3. Colorectal Surgery Unit, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    Alexander G. Heriot MA, MB, BChir, MD, MBA, FRCS (Gen.), FRCSEd, FRACS, FACS

Authors
  1. Nicholas Smith MBBS, FRACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peadar S. Waters MB, BCh, BAO, MD, MCH, MedED, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Oliver Peacock BMBS, PhD, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph C. Kong MBBS, FRACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacob McCormick MBBS, FRACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satish K. Warrier MBBS, MS, FRACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Orla McNally MBBAO, BCh, FRCSI, MRCOG, FRANZCOG, CGO
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrew C. Lynch MBChB, MMedSc, FRACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alexander G. Heriot MA, MB, BChir, MD, MBA, FRCS (Gen.), FRCSEd, FRACS, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander G. Heriot MA, MB, BChir, MD, MBA, FRCS (Gen.), FRCSEd, FRACS, FACS.

Ethics declarations

Disclosures

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Nicholas Smith and Peadar S. Waters are co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smith, N., Waters, P.S., Peacock, O. et al. Pelvic Exenteration for Anal and Urogenital Squamous Cell Carcinoma: Experience and Outcomes from an Exenteration Unit Over 12 Years. Ann Surg Oncol 27, 2450–2456 (2020). https://doi.org/10.1245/s10434-020-08229-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08229-8

Search

Navigation